2,4-Diaminopyrimidines as Potent Inhibitors of Trypanosoma brucei and Identification of Molecular Targets by a Chemical Proteomics Approach
2011

New Drug Candidate SCYX-5070 for Treating Sleeping Sickness

Sample size: 6 publication 10 minutes Evidence: high

Author Information

Author(s): Mercer Luke, Bowling Tana, Perales Joe, Freeman Jennifer, Nguyen Tien, Bacchi Cyrus, Yarlett Nigel, Don Robert, Jacobs Robert, Nare Bakela

Primary Institution: SCYNEXIS Inc.

Hypothesis

Can 2,4-diaminopyrimidines serve as effective inhibitors of Trypanosoma brucei?

Conclusion

The study found that SCYX-5070 is a potent inhibitor of Trypanosoma brucei and shows promise as a treatment for human African trypanosomiasis.

Supporting Evidence

  • SCYX-5070 cured acute trypanosomiasis in mice without toxicity.
  • 2,4-diaminopyrimidines showed a good pharmacological profile against trypanosomatid protozoans.
  • MAPKs and CRKs were identified as potential molecular targets for SCYX-5070.

Takeaway

Scientists discovered a new medicine that can kill the germs causing sleeping sickness in mice, which could help people who are sick.

Methodology

The study involved in vitro and in vivo testing of SCYX-5070 against Trypanosoma brucei, including time kill assays and efficacy in a mouse model.

Limitations

The study primarily focused on in vitro and mouse models, which may not fully represent human responses.

Participant Demographics

Female Swiss Webster mice were used in the animal model.

Digital Object Identifier (DOI)

10.1371/journal.pntd.0000956

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication